Outcomes of the 63-μm Gelatin Microstent Versus 45-μm Gelatin Microstent: An International Multicenter Study.

PURPOSE

To compare 12-month effectiveness and safety of 63-μm gelatin microstent (Xen63) versus 45-μm gelatin microstent (Xen45).

DESIGN

Multicenter, retrospective cohort study.

SUBJECTS

Two hundred eyes of 200 patients (100 in each Xen63 and Xen45 group), with or without phacoemulsification.

METHODS

Consecutive patients undergoing 63-μm microstent implantation across 4 countries (Canada, Italy, Austria, and Belgium) were compared with matched controls who underwent 45-μm microstent implantation.

MAIN OUTCOME MEASURES

Primary outcome measure was the probability of complete success at 1 year: (1) no 2 consecutive intraocular pressure (IOP) >14 or 0.05). At 12 months, the 63-μm group had significantly lower IOP (mean, 14.6 ± 7.6 vs. 15.8 ± 6.1 mmHg; P = 0.021) and medication count (0.6 ± 1.1 vs. 1.1 ± 1.5; P = 0.024). Postoperative needling was performed in 16.0% and 18.0% of 63- and 45-μm microstent-implanted eyes, respectively. Incidence of early postoperative choroidal effusion was higher in the 63-μm group (25.0% vs. 6.0%; P 0.050).

CONCLUSIONS

Xen63 demonstrated superior IOP-lowering effectiveness compared with its 45-μm variant in patients requiring more robust IOP targets. Xen63-implanted eyes experienced a higher incidence of early postoperative choroidal effusion, the majority of which were transient. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.